X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The agreement forms the basis for discussions on the introduction, development and commercialization of KIN001, a patented combination of two APIs, pamapimod and pioglitazone, for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KIN001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ChaoDian
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 10, 2023
Details:
KIN001 is a patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Infections and Infectious Diseases Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
KIN001 is an orally administered combination of pamapimod and pioglitazone. Pamapimod is a p38 MAPK inhibitor, whereas pioglitazone is a PPAR gamma activator. It is currently being developed in COVID-19, Idiopathic Pulmonary Fibrosis and wet Age-Related Macular Degeneration.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KIN001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
KIN001 is an orally available patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
Lead Product(s): Pamapimod
Therapeutic Area: Infections and Infectious Diseases Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
KIN001 is combination of two APIs: pamapimod and pioglitazone. Kinarus has found that combining pamapimod with pioglitazone, leads to synergistic efficacy and increased duration of action in preclinical models of wet AMD, IPF and fibrotic and inflammatory diseases.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Ophthalmology Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
KIN001 is a patented combination of two active pharmaceutical ingredients (APIs): pamapimod and pioglitazone. Pamapimod is a highly selective clinical stage small molecule inhibitor of the p38 MAP kinase signaling pathway.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Ophthalmology Product Name: KIN001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Great Health Companion Group Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 16, 2022
Details:
KIN001 is an orally administered combination of two drugs that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Infections and Infectious Diseases Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
KIN001 (pamapimod) is a proprietary novel combination of two active pharmaceutical ingredients that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis in preclinical studies.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Infections and Infectious Diseases Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
KIN001 (pamapimod) has been shown to reduce pathological blood vessel growth (neovascularization) in the choroid of the eye in preclinical models of wAMD.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Ophthalmology Product Name: KIN001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
KIN001, a combination of p38 MAPK inhibitor pamapimod with a second drug has a proven safety record with potential to address a broad range of indications.
Lead Product(s): Pamapimod,Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
